-DOCSTART- -X- O
Human -X- _ O
coronaviruses -X- _ O
( -X- _ O
HCoVs -X- _ O
) -X- _ O
, -X- _ O
including -X- _ O
severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
coronavirus -X- _ O
( -X- _ O
SARSCoV -X- _ O
) -X- _ O
and -X- _ O
2019 -X- _ B-Patient
novel -X- _ I-Patient
coronavirus -X- _ I-Patient
( -X- _ I-Patient
2019-nCoV -X- _ I-Patient
, -X- _ I-Patient
also -X- _ I-Patient
known -X- _ I-Patient
as -X- _ I-Patient
SARS-CoV-2 -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
lead -X- _ O
global -X- _ O
epidemics -X- _ O
with -X- _ O
high -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
However -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
currently -X- _ O
no -X- _ O
effective -X- _ O
drugs -X- _ O
targeting -X- _ O
2019-nCoV -X- _ B-Patient
/ -X- _ I-Patient
SARS-CoV-2. -X- _ I-Patient
Drug -X- _ B-Intervention
repurposing -X- _ I-Intervention
, -X- _ O
representing -X- _ O
as -X- _ O
an -X- _ O
effective -X- _ O
drug -X- _ O
discovery -X- _ O
strategy -X- _ O
from -X- _ O
existing -X- _ O
drugs -X- _ O
, -X- _ O
could -X- _ O
shorten -X- _ O
the -X- _ O
time -X- _ O
and -X- _ O
reduce -X- _ O
the -X- _ O
cost -X- _ O
compared -X- _ O
to -X- _ O
de -X- _ O
novo -X- _ O
drug -X- _ O
discovery. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
present -X- _ O
an -X- _ O
integrative -X- _ O
, -X- _ O
antiviral -X- _ B-Intervention
drug -X- _ I-Intervention
repurposing -X- _ I-Intervention
methodology -X- _ I-Intervention
implementing -X- _ I-Intervention
a -X- _ I-Intervention
systems -X- _ I-Intervention
pharmacology-based -X- _ I-Intervention
network -X- _ I-Intervention
medicine -X- _ I-Intervention
platform -X- _ I-Intervention
, -X- _ I-Intervention
quantifying -X- _ I-Intervention
the -X- _ I-Intervention
interplay -X- _ I-Intervention
between -X- _ I-Intervention
the -X- _ I-Intervention
HCoV–host -X- _ I-Intervention
interactome -X- _ I-Intervention
and -X- _ I-Intervention
drug -X- _ I-Intervention
targets -X- _ I-Intervention
in -X- _ I-Intervention
the -X- _ I-Intervention
human -X- _ I-Intervention
protein–protein -X- _ I-Intervention
interaction -X- _ I-Intervention
network. -X- _ I-Intervention
Phylogenetic -X- _ O
analyses -X- _ O
of -X- _ O
15 -X- _ O
HCoV -X- _ O
whole -X- _ O
genomes -X- _ O
reveal -X- _ O
that -X- _ O
2019-nCoV -X- _ B-Patient
/ -X- _ I-Patient
SARS-CoV-2 -X- _ I-Patient
shares -X- _ O
the -X- _ O
highest -X- _ O
nucleotide -X- _ O
sequence -X- _ O
identity -X- _ O
with -X- _ O
SARS-CoV -X- _ O
( -X- _ O
79.7 -X- _ O
% -X- _ O
) -X- _ O
. -X- _ O
Specifically -X- _ O
, -X- _ O
the -X- _ O
envelope -X- _ O
and -X- _ O
nucleocapsid -X- _ O
proteins -X- _ O
of -X- _ O
2019-nCoV -X- _ O
/ -X- _ O
SARS-CoV-2 -X- _ O
are -X- _ O
two -X- _ O
evolutionarily -X- _ O
conserved -X- _ O
regions -X- _ O
, -X- _ O
having -X- _ O
the -X- _ O
sequence -X- _ O
identities -X- _ O
of -X- _ O
96 -X- _ O
% -X- _ O
and -X- _ O
89.6 -X- _ O
% -X- _ O
, -X- _ O
respectively -X- _ O
, -X- _ O
compared -X- _ O
to -X- _ O
SARS-CoV. -X- _ O
Using -X- _ B-Outcome
network -X- _ I-Outcome
proximity -X- _ I-Outcome
analyses -X- _ I-Outcome
of -X- _ I-Outcome
drug -X- _ I-Outcome
targets -X- _ I-Outcome
and -X- _ I-Outcome
HCoV–host -X- _ I-Outcome
interactions -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
interactome -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
prioritize -X- _ I-Outcome
16 -X- _ I-Outcome
potential -X- _ I-Outcome
anti-HCoV -X- _ I-Outcome
repurposable -X- _ I-Outcome
drugs -X- _ I-Outcome
( -X- _ I-Outcome
e.g. -X- _ I-Outcome
, -X- _ I-Outcome
melatonin -X- _ I-Outcome
, -X- _ I-Outcome
mercaptopurine -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
sirolimus -X- _ I-Outcome
) -X- _ I-Outcome
that -X- _ I-Outcome
are -X- _ I-Outcome
further -X- _ I-Outcome
validated -X- _ I-Outcome
by -X- _ I-Outcome
enrichment -X- _ I-Outcome
analyses -X- _ I-Outcome
of -X- _ I-Outcome
drug-gene -X- _ I-Outcome
signatures -X- _ I-Outcome
and -X- _ I-Outcome
HCoV-induced -X- _ I-Outcome
transcriptomics -X- _ I-Outcome
data -X- _ I-Outcome
in -X- _ I-Outcome
human -X- _ I-Outcome
cell -X- _ I-Outcome
lines. -X- _ I-Outcome
We -X- _ I-Outcome
further -X- _ I-Outcome
identify -X- _ I-Outcome
three -X- _ I-Outcome
potential -X- _ I-Outcome
drug -X- _ I-Outcome
combinations -X- _ I-Outcome
( -X- _ I-Outcome
e.g. -X- _ I-Outcome
, -X- _ I-Outcome
sirolimus -X- _ I-Outcome
plus -X- _ I-Outcome
dactinomycin -X- _ I-Outcome
, -X- _ I-Outcome
mercaptopurine -X- _ I-Outcome
plus -X- _ I-Outcome
melatonin -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
toremifene -X- _ I-Outcome
plus -X- _ I-Outcome
emodin -X- _ I-Outcome
) -X- _ I-Outcome
captured -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
“Complementary -X- _ I-Outcome
Exposure” -X- _ I-Outcome
pattern -X- _ I-Outcome
: -X- _ I-Outcome
the -X- _ I-Outcome
targets -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
drugs -X- _ I-Outcome
both -X- _ I-Outcome
hit -X- _ I-Outcome
the -X- _ I-Outcome
HCoV–host -X- _ I-Outcome
subnetwork -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
target -X- _ I-Outcome
separate -X- _ I-Outcome
neighborhoods -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
interactome -X- _ I-Outcome
network. -X- _ I-Outcome
In -X- _ O
summary -X- _ O
, -X- _ O
this -X- _ O
study -X- _ O
offers -X- _ O
powerful -X- _ O
network-based -X- _ O
methodologies -X- _ O
for -X- _ O
rapid -X- _ O
identification -X- _ O
of -X- _ O
candidate -X- _ O
repurposable -X- _ O
drugs -X- _ O
and -X- _ O
potential -X- _ O
drug -X- _ O
combinations -X- _ O
targeting -X- _ O
2019-nCoV -X- _ O
/ -X- _ O
SARS-CoV-2 -X- _ O
. -X- _ O

